Precision Cancer Immunotherapy
Adularia AG
Incorporated
05.09.2022Headquarters
Zurich ETH ZentrumSupport
At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the bodys native immune response against cancer.
News
University Hospital Zurich's Health Innovation Hub expands portfolio (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Kickfund invests at full throttle (startupticker.ch)
The Biomedical Entrepreneurship ecosystem: Turning cutting-edge research into viable ventures (venturelab.swiss)
Recolony to bring its immunotherapy into pre-clinical phase (startupticker.ch)
Recolony wins CHF 150,000 to advance a revolutionary cancer immunotherapy (venturekick.ch)
InnoBooster accelerates four new projects (startupticker.ch)
Venture Leaders Biotech 2022: Captain’s blog by Recolony CEO Ana Montalban-Arques (venturelab.swiss)
The Venture Leaders Biotech impress international investors and industry leaders in Boston (venturelab.swiss)
Recolony: The Venture Leader Biotech developing bacteria-based therapy to treat cancer (venturelab.swiss)
"Innovation needs diversity" — Interview with Maria Olivares of the Innovation Hub at the University of Zürich (venturelab.swiss)
The Venture Leaders Biotech 2022 kick-off their roadshow to Boston and Cambridge (venturelab.swiss)
Milestones news
Starting the production of drug substance
Scientific Advice meeting with Swissmedic
Recolony is incorporated as an AG/Ltd./SA
Documents
